In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK takes exclusive rights to Amicus' Fabry compound Amigal; terminated

Executive Summary

Exactly a year after Shire Human Genetic Therapies returned rights to Amigal (AT1001; HG3310; migalastat), Amicus Therapeutics Inc. (orphan diseases) has selected GlaxoSmithKline PLC as its new exclusive worldwide partner to develop, manufacture, and market the Phase III Fabry disease candidate.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies